Trial Profile
First in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Adverse reactions; First in man
- Acronyms PioPAP
- 15 Jan 2020 Status changed from active, no longer recruiting to completed.
- 31 Jan 2019 Planned End Date changed from 1 Jul 2018 to 1 Jun 2020.
- 31 Jan 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Jun 2019.